IDH1 and neoplasm: Tumor-derived IDH1 mutation sensitizes cells to ferroptosis, and inhibition of mutant IDH1 produces the oncometabolite D-2-hydroxyglutarate (D-2-HG), which confers resistance to erastin-induced ferroptosis.